Trial Profile

Adjuvant Trastuzumab Plus Pyrotinib for Residual Invasive HER2-positive Breast Cancer After Neoadjuvant Chemotherapy Plus Anti-HER2 Target Therapy

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 24 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pyrotinib (Primary) ; Trastuzumab (Primary)
Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
Focus Therapeutic Use

Most Recent Events

18 Nov 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2026.
19 Apr 2022 Status changed from not yet recruiting to recruiting.
11 Feb 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com